Cidara's Narrow Spread: The Bidding War Is Over

Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Immunovant, Inc. (NASDAQ:IMVT) Q2 2026 Earnings Call Transcript

Q2 2026 Earnings Call Transcript November 10, 2025 Immunovant, Inc. misses on earnings expectations. Reported EPS is ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2026 Earnings Call Transcript

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...
The Manila Times

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing ...

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided ...

/C O R R E C T I O N from source -- argenx Canada Inc./

SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a ...

argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders

Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological ...
The Caledonian Record

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations ...

EXTON, PA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S.
Investing

Argenx rises after Q3 earnings beat on strong sales growth

Investing.com -- Argenx (EBR:ARGX) shares climbed more than 2% on Thursday after the Belgian biopharmaceutical company reported third-quarter results that exceeded forecasts, led by stronger product ...

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in ...